Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer

被引：0
|
作者：
da Silva, Leonardo Roberto
Sartori, Guilherme
Ramalho, Susana
Reinert, Tomas
Da Rosa, Mahira Lopes
Tavares, Grazielle Morais
Mantovani, Higor
Vasconcelos, Vivian
Cabello, Ana Elisa Ribeiro Da Silva
Coelho, Guilherme
Mandelli, Jovana
Zaffaroni, Facundo
Barrios, Carlos
Graudenz, Marcia Silveira
Cabello, Cesar
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-17-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-17-12
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Yu, Yue
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [42] Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
    Zhao, Yingying
    Chen, Xinru
    Wang, Yaohui
    Zhang, Xueqing
    Ye, Yumei
    Xu, Shuguang
    Zhou, Liheng
    Lin, Yanping
    Lu, Jingsong
    Yin, Wenjin
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [43] Prognostic impact of axillary lymph node status after neoadjuvant chemotherapy for patients with breast cancer
    Nakamura, R.
    Yamamoto, N.
    Miyaki, T.
    Itami, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
    Ma, Youzhao
    Zhu, Mingda
    Zhang, Jingyang
    Lv, Minhao
    Chen, Xiuchun
    Liu, Zhenzhen
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1210 - 1221
  • [45] Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    BREAST, 2024, 73
  • [46] Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer
    Reinert, Tomas
    Sartori, Guilherme Parisotto
    Souza, Alessandra A. B.
    Pellegrini, Rodrigo
    Rosa, Mahira L.
    Rossatto, Nathalia
    Coelho, Guilherme P.
    Litvin, Isnard E.
    Zerwes, Felipe
    Millen, Eduardo
    Cavalcante, Francisco P.
    Frasson, Antonio L.
    Graudenz, Marcia S.
    Barrios, Carlos H.
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Dynamic Changes of HER2 Expression in Breast Cancers after Neoadjuvant Chemotherapy with the Inclusion of HER2-low Category
    Karakas, Cansu
    Tyburski, Haley
    Liu, Elena
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2023, 103 (03) : S151 - S152
  • [48] Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Gong, G.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S624 - S624
  • [49] Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis
    Yingbo Shao
    Yang Yu
    Zhifen Luo
    Huijuan Guan
    Fangyuan Zhu
    Yaning He
    Qi Chen
    Chaojun Liu
    Bing Nie
    Hui Liu
    Annals of Surgical Oncology, 2022, 29 : 8026 - 8034
  • [50] Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis
    Shao, Yingbo
    Yu, Yang
    Luo, Zhifen
    Guan, Huijuan
    Zhu, Fangyuan
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Nie, Bing
    Liu, Hui
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (13) : 8026 - 8034
12345